日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices

转移性非小细胞肺癌患者的生物标志物检测率和模式：一项社区实践中的前瞻性观察研究

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO-25-00832
Evangelist, Makenzi; Wang, Bo; Butrynski, James E; Paschold, John; Ward, Patrick J; Waterhouse, David M; Jotte, Robert M; Ali, Kashif; Richards, Donald A; Konduri, Kartik; Melnyk, Anton; Owera, Rami S; Hakimian, David; Ghaddar, Habib; Lander, Eric M; Robert, Nicholas J; Yori, Jennifer L; Upadhyay, Vikalp; Spigel, David R; Johnson, Melissa L
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer

Sacituzumab Govitecan治疗晚期实体瘤患者的疗效和安全性（TROPiCS-03）：晚期子宫内膜癌患者的分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.23.02767
Santin, Alessandro D; Corr, Bradley R; Spira, Alexander; Willmott, Lyndsay; Butrynski, James; Tse, Ka Yu; Patel, Jilpa; Mekan, Sabeen; Wu, Tia; Lin, Kai-Wen; Kuo, Peiwen; Dumbrava, Ecaterina E
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2024
文献求助 收藏

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium

肿瘤临床药师干预对美国肿瘤网络MYLUNG联盟临床试验入组的影响

期刊:
影响因子:
doi:10.6004/jadpro.2024.15.8.7
Koselke, Elizabeth; Kaspin-Powell, Lisa C; Hough, Shannon; Howell, Joshua; Robert, Nicholas J; Neubauer, Marcus A; Bullock, Susie A; Walberg, Jennifer M; Rammage, Melissa; Butrynski, James E; Hakimian, David; Jotte, Robert M; Meshad, Michael W; Ali, Kashif; Waterhouse, David Michael; Coleman, Robert L; Evangelist, Makenzi Colleen
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

瑞戈非尼治疗转移性和/或不可切除的胃肠道间质瘤患者（标准酪氨酸激酶抑制剂治疗失败后）的多中心II期试验的长期随访结果

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw228
Ben-Ami, E; Barysauskas, C M; von Mehren, M; Heinrich, M C; Corless, C L; Butrynski, J E; Morgan, J A; Wagner, A J; Choy, E; Yap, J T; Van den Abbeele, A D; Solomon, S M; Fletcher, J A; Demetri, G D; George, S
信号转导
发表日期：2016
文献求助 收藏

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

口服组蛋白去乙酰化酶抑制剂阿贝西诺他联合多柔比星治疗转移性肉瘤患者的I期研究

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.29175
Choy, Edwin; Flamand, Yael; Balasubramanian, Sriram; Butrynski, James E; Harmon, David C; George, Suzanne; Cote, Gregory M; Wagner, Andrew J; Morgan, Jeffrey A; Sirisawad, Mint; Mani, Chitra; Hornicek, Francis J; Duan, Zhenfeng; Demetri, George D
乙酰化
表观遗传
发表日期：2015
文献求助 收藏

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

一项多中心 II 期研究，评估帕唑帕尼在至少接受过伊马替尼和舒尼替尼治疗失败的晚期胃肠道间质瘤 (GIST) 患者中的疗效。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdt484
Ganjoo, K N; Villalobos, V M; Kamaya, A; Fisher, G A; Butrynski, J E; Morgan, J A; Wagner, A J; D'Adamo, D; McMillan, A; Demetri, G D; George, S
发表日期：2014
文献求助 收藏

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

一项评估缺氧激活前药TH-302联合多柔比星治疗晚期软组织肉瘤患者的安全性和抗肿瘤活性的II期研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2013.54.3660
Chawla, Sant P; Cranmer, Lee D; Van Tine, Brian A; Reed, Damon R; Okuno, Scott H; Butrynski, James E; Adkins, Douglas R; Hendifar, Andrew E; Kroll, Stew; Ganjoo, Kristen N
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

奥拉帕尼治疗标准化疗失败后难治性尤文氏肉瘤患者的II期研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-14-813
Choy, Edwin; Butrynski, James E; Harmon, David C; Morgan, Jeffrey A; George, Suzanne; Wagner, Andrew J; D'Adamo, David; Cote, Gregory M; Flamand, Yael; Benes, Cyril H; Haber, Daniel A; Baselga, Jose M; Demetri, George D
发表日期：2014
文献求助 收藏

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

瑞戈非尼对伊马替尼和舒尼替尼治疗失败后转移性和/或不可切除的胃肠道间质瘤患者的疗效和安全性：一项多中心 II 期试验

期刊:Journal of Clinical Oncology
影响因子:42.1
doi:10.1200/JCO.2011.39.9394
Suzanne George, Qian Wang, Michael C Heinrich, Christopher L Corless, Meijun Zhu, James E Butrynski, Jeffrey A Morgan, Andrew J Wagner, Edwin Choy, William D Tap, Jeffrey T Yap, Annick D Van den Abbeele, Judith B Manola, Sarah M Solomon, Jonathan A Fletcher, Margaret von Mehren, George D Demetri
肿瘤
胃癌
WB
发表日期：2012
文献求助 收藏

Esophageal gastrointestinal stromal tumor: report of 7 patients

食管胃肠道间质瘤：7例患者报告

期刊:Cancer Imaging
影响因子:3.5
doi:10.1102/1470-7330.2012.0017
Shinagare, A B; Zukotynski, K A; Krajewski, K M; Jagannathan, J P; Butrynski, J; Hornick, J L; Ramaiya, N H
发表日期：2012
文献求助 收藏